Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc. is a drug development company based in Taichung, Taiwan, focused on long-acting release drug products for CNS disorders and chronic diseases. Its lead product, ALA-1000, is being developed for the treatment of opioid use disorder. Pre-clinical stage products include ALA-1300 and ALA-2000 for opioid use disorder, ALA-4000 for Parkinson's disease, ALA-3000 for treatment-resistant depression, and ALA-5000 for schizophrenia. The company was founded in 2016.